Avalo Therapeutics, Inc. announced its financial results for the year ended December 31, 2025, reporting a net loss of $78.3 million, research and development expenses of $50.1 million, and cash, cash equivalents, and short-term investments of $98.3 million expected to fund operations into 2028. Topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) for hidradenitis suppurativa is expected in the second quarter of 2026.
Key takeaways
Topline data expected from Phase 2 LOTUS trial of abdakibart (AVTX-009) in Q2 2026 for approximately 250 adults with hidradenitis suppurativa.
Cash, cash equivalents, and short-term investments of $98.3 million as of December 31, 2025, expected to provide runway into 2028.
Net loss of $78.3 million for year ended December 31, 2025, compared to $35.1 million for 2024.
Research and development expenses of $50.1 million for 2025, increase of $25.6 million from 2024.
General and administrative expenses of $22.9 million for 2025, increase of $5.7 million from 2024.
Basic net loss per share of $5.84 for 2025 based on 13,404,830 weighted average common shares outstanding.